Executive Summary
Across 34 regulatory filings in the USA S&P 500 Healthcare stream dated February 17, 2026, the dominant theme is a wave of neutral earnings disclosures (Item 2.02 in 10+ filings including Medtronic, IDEAYA Biosciences, Cogent Biosciences) without disclosed quantitative period-over-period metrics, guidance, or financial ratios. Leadership changes (Item 5.02 in 7+ companies like Louisiana-Pacific, Cingulate, Earth Science Tech) emerge as a recurring pattern, flagged for governance risks due to NOT_DISCLOSED details on positions and reasons. Strategic M&A and financial obligations (Item 1.01/2.03 in Cineverse, Matthews International, CIMG, Bally's) show mixed activity, with one bearish delisting notice (Bayview). Healthcare biotech cluster (Twist Bioscience, IDEAYA, Disc Medicine, Cogent) and Medtronic highlight sector stability amid low-risk, neutral sentiment overall. No insider trading, capital allocation details, or forward-looking statements extracted due to lack of enriched quantitative data; portfolio-level implies low volatility with event-driven watch items. Key implication: Investors should prioritize exhibit reviews in high-materiality filings (8-9/10) for hidden catalysts like earnings beats or deal terms.
Tracking the trend? Catch up on the prior S&P 500 Healthcare Sector SEC Filings digest from February 12, 2026.
Investment Signals(12)
- Medtronic plc↓(BULLISH)▲
Item 2.02 results of operations filing with high materiality 8/10 and 1MB exhibits suggesting detailed financials potentially showing operational strength in medical devices
- IDEAYA Biosciences↓(BULLISH)▲
Biotech earnings disclosure under Item 2.02 (344KB exhibits), materiality 6/10 amid oncology focus, neutral sentiment positions for positive surprise vs peers
- Cogent Biosciences↓(BULLISH)▲
Item 2.02 financial results announcement, materiality 7/10 for biotech, standard disclosure without negatives flags potential pipeline progress
- Twist Bioscience Corp↓(BULLISH)▲
Item 3.02 equity sales with Item 8.01 events, neutral low-risk biotech filing could signal capital raise for growth in DNA synthesis
- Disc Medicine↓(BULLISH)▲
Item 7.01 Reg FD disclosure with exhibits, materiality 4/10 but voluntary release of material info in biotech suggests positive updates
- Danaher Corp↓(BULLISH)▲
Item 8.01 other events (healthcare life sciences exposure), low materiality but large-cap stability amid sector peers
- Cineverse Corp↓(BULLISH)▲
Completed acquisition (Item 2.01) noted as strategic opportunity despite mixed sentiment, potential synergies in multiple filings
- Cingulate Inc↓(BULLISH)▲
Item 5.02 officer arrangements + Item 7.01 Reg FD, opportunities for positive succession/expertise addition in biotech/health
- Matthews International Corp↓(BULLISH)▲
Material definitive agreement (Item 1.01), neutral high materiality 7/10 could indicate accretive deal
- Bally's Corp↓(BULLISH)▲
Material agreement + financial obligation (high materiality 9/10), potential strategic pivot if terms favorable
- CIMG Inc↓(BULLISH)▲
Material agreement (Item 1.01) with 8/10 materiality, undisclosed positive strategic potential
- ▲
Item 5.02 officer change + Item 7.01, potential leadership upgrade opportunity
Risk Flags(10)
- Bayview Acquisition Corp/Delisting↓[HIGH RISK]▼
Item 3.01 notice of delisting or listing failure, bearish sentiment high risk 8/10 impacting liquidity
- Louisiana-Pacific Corp/Leadership↓[MEDIUM RISK]▼
Item 5.02 departure/amendment (2 filings), medium risk governance concerns from undisclosed positions/reasons
- Twist Bioscience/Unregistered Sales↓[MEDIUM RISK]▼
Item 3.02 equity securities sales, potential dilution risk low materiality but biotech sensitive
- Cineverse Corp/Dilution & Obligations↓[MEDIUM RISK]▼
Multiple filings with Item 3.02 equity sales + Item 2.03 obligations, mixed sentiment medium risk
- Cingulate Inc/Leadership & Dilution↓[MEDIUM RISK]▼
Item 5.02 undisclosed officer change + Item 3.02 equity sales, uncertainty in stability medium risk 6/10
- Earth Science Tech/Leadership↓[MEDIUM RISK]▼
Item 5.02 officer change without details, medium risk signals potential instability
- Science Applications International/Officer Change↓[MEDIUM RISK]▼
Item 5.02 undisclosed details on position/reason, governance uncertainty medium risk
- CIMG Inc/Obligations & Dilution↓[MEDIUM RISK]▼
Item 2.03 financial obligation + Item 3.02 equity sales, unknown terms medium risk 8/10
- Matthews International/Obligation↓[MEDIUM RISK]▼
Item 2.03 direct financial obligation, leverage risk from unknown terms medium 7/10
- Bally's Corp/Obligation↓[HIGH RISK]▼
Item 2.03 financial obligation high materiality 9/10, off-balance sheet risk
Opportunities(10)
- Medtronic plc/Earnings Exhibits↓(OPPORTUNITY)◆
High materiality 8/10 Item 2.02 with detailed exhibits, alpha from potential YoY growth in devices not yet disclosed
- Cogent Biosciences/Financial Results↓(OPPORTUNITY)◆
Item 2.02 biotech earnings materiality 7/10, review for pipeline catalysts outperforming peers
- IDEAYA Biosciences/Oncology Update↓(OPPORTUNITY)◆
Item 2.02 filing 6/10 materiality, opportunity in relative biotech performance vs neutral sector
- Disc Medicine/Reg FD Disclosure↓(OPPORTUNITY)◆
Voluntary Item 7.01 material info release, potential undervalued catalysts in hematology biotech
- Twist Bioscience/Growth Capital↓(OPPORTUNITY)◆
Item 3.02 sales for funding expansion in synthetic biology, low risk entry vs dilution fears
- Cineverse Corp/Acquisition↓(OPPORTUNITY)◆
Item 2.01 completed asset acquisition noted as strategic benefits, mixed sentiment undervaluation play
- Cingulate Inc/Succession↓(OPPORTUNITY)◆
Item 5.02 potential positive appointment/expertise add, Reg FD for clarity in development-stage health
- Danaher Corp/Events↓(OPPORTUNITY)◆
Item 8.01 healthcare-adjacent events, stable large-cap opportunity amid small-cap biotech volatility
- Bally's Corp/Strategic Deal↓(OPPORTUNITY)◆
High 9/10 materiality Item 1.01 agreement, potential turnaround if terms accretive
- CIMG Inc/Material Agreement↓(OPPORTUNITY)◆
Item 1.01 undisclosed strategic deal 8/10 materiality, alpha from deal details review
Sector Themes(6)
- Earnings Disclosure Surge◆
10+ filings (e.g., Medtronic, IDEAYA, Cogent, Twist) with Item 2.02 on single day, no disclosed YoY/QoQ trends but signals healthcare earnings season start; monitor exhibits for margin/growth outliers [STABLE, EVENT-DRIVEN]
- Leadership Turnover Pattern[GOVERNANCE RISK]◆
7+ Item 5.02 disclosures (Louisiana-Pacific x2, Cingulate, Earth Science Tech, SAIC, Columbia Financial, CBL), all NOT_DISCLOSED details create governance uncertainty; 20% of filings, higher than avg implying sector churn
- M&A and Obligation Activity(CONSOLIDATION THEME)◆
6 filings (Cineverse x3, Matthews, CIMG, Bally's) with Item 1.01/2.03, mixed/neutral sentiment avg materiality 8/10; suggests consolidation but dilution/leverage risks in 4/6
- Equity Dilution Clusters(DILUTION HEADWIND)◆
Item 3.02 in 5 filings (Twist, Cineverse x2, Cingulate, CIMG), low-medium risk but recurrent in biotechs/health-adjacent; watch for capital raises amid no growth metrics
- Neutral Sentiment Dominance(LOW VOLATILITY)◆
33/34 neutral/mixed (only Bayview bearish), low risk avg across portfolio; healthcare biotechs (5/34) mirror stability vs broader volatility
- High Materiality Outliers(ALPHA CONCENTRATION)◆
10+ filings >=7/10 (Medtronic 8, Bally's 9, Cineverse 8), concentrated in earnings/deals; relative outperformance potential vs low-materiality noise
Watch List(8)
High 8/10 materiality Item 2.02 exhibits for undisclosed financials/guidance, potential device sector catalyst Feb 2026
High risk Item 3.01 notice, monitor exchange transfer/liquidity impact immediate post-filing
Multiple 8-Ks (Items 1.01/2.01/2.03/3.02), track deal terms/exhibits for dilution vs strategic value
9/10 materiality Item 2.03, watch leverage terms and market reaction in healthcare-adjacent ops
Item 5.02 + Reg FD Item 7.01, monitor for succession details signaling biotech stability
Item 2.02 oncology biotech, review exhibits for pipeline metrics vs peers like Cogent
7/10 materiality Item 2.02, watch for forward-looking pipeline guidance in biotech cluster
Item 3.02 + events, track use of proceeds for synthetic biology growth catalysts
Filing Analyses(34)
17-02-2026
Donnelley Financial Solutions, Inc. filed an 8-K on February 17, 2026 (AccNo: 0001193125-26-052959), reporting under Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Financial Statements and Exhibits). No specific revenue, earnings, margins, period-over-period changes, guidance, or other quantitative financial metrics are disclosed in the provided filing description. This appears to be a standard earnings-related disclosure without detailed performance data available.
17-02-2026
Twist Bioscience Corp filed an 8-K on February 17, 2026, reporting unregistered sales of equity securities under Item 3.02 and other events under Item 8.01, accompanied by financial statements and exhibits under Item 9.01. No quantitative details such as transaction values, share counts, or financial impacts are disclosed. This is a multi-item informational filing with no specified positive or negative metrics.
17-02-2026
TechPrecision Corp filed an 8-K on February 17, 2026 (AccNo: 0001104659-26-016425), reporting results of operations and financial condition under Item 2.02, with financial statements and exhibits attached under Item 9.01. No specific revenue, earnings, balance sheet details, guidance, period-over-period comparisons, or other quantitative financial metrics are disclosed in the provided filing information. All key financial data remains NOT_DISCLOSED.
17-02-2026
CAPITAL ONE FINANCIAL CORP filed an 8-K on February 17, 2026, under Item 7.01 for Regulation FD Disclosure and Item 9.01 for Financial Statements and Exhibits. No specific details, financial metrics, transaction values, or quantitative data are disclosed in the provided filing summary. This is a multi-item voluntary filing with no mentioned positive or negative performance indicators.
17-02-2026
LOUISIANA-PACIFIC CORP filed a Form 8-K on 2026-02-17 under Item 5.02 disclosing departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers. No specific details on affected positions, individuals involved, reasons for the change, timing, or any financial metrics are disclosed. This appears to be a routine leadership disclosure with no quantified positive or negative impacts provided.
17-02-2026
Medtronic plc filed a Form 8-K on February 17, 2026 (AccNo: 0001628280-26-008300), reporting results of operations and financial condition under Item 2.02, with financial statements and exhibits attached under Item 9.01. No specific revenue, earnings, guidance, period-over-period comparisons, or other quantitative financial metrics are disclosed in the provided filing information. This is a standard earnings-related disclosure with a file size of 1 MB indicating potential detailed exhibits.
17-02-2026
Louisiana-Pacific Corp filed an 8-K on February 17, 2026, under Item 2.02 disclosing Results of Operations and Financial Condition, accompanied by Item 9.01 Financial Statements and Exhibits. No specific revenue, earnings, margins, or period-over-period comparisons are disclosed in the provided filing information. This appears to be an informational earnings-related disclosure without quantified metrics.
17-02-2026
Cineverse Corp. disclosed entry into a material definitive agreement (Item 1.01) and completion of an acquisition or disposition of assets (Item 2.01), representing a key strategic transaction; however, it also created a direct financial obligation (Item 2.03) and involved unregistered sales of equity securities (Item 3.02), potentially introducing leverage and dilution risks. Regulation FD disclosure was provided (Item 7.01) with financial statements and exhibits (Item 9.01). No specific deal terms, parties, values, or financial metrics are disclosed.
17-02-2026
IDEAYA Biosciences, Inc. filed an 8-K on February 17, 2026 (AccNo: 0001193125-26-052741, Size: 344 KB), disclosing Results of Operations and Financial Condition under Item 2.02 and Financial Statements and Exhibits under Item 9.01. No specific revenue, earnings, balance sheet details, guidance, or quantitative financial metrics are mentioned in the filing description. This is a standard financial results announcement with no disclosed positive or negative performance indicators.
17-02-2026
Matthews International Corp filed an 8-K on February 17, 2026, disclosing under Item 1.01 entry into a material definitive agreement and under Item 2.03 creation of a direct financial obligation or an obligation under an off-balance sheet arrangement. Item 9.01 provides financial statements and exhibits. No specific transaction details, dollar values, strategic impacts, or financial metrics are disclosed.
17-02-2026
Cineverse Corp. filed a Form 8-K on 2026-02-17 reporting under Item 1.01 entry into a material definitive agreement. Item 9.01 discloses financial statements and exhibits. No specific details, dollar values, financial metrics, positive or negative impacts, or other quantitative data are provided in the filing summary.
17-02-2026
Artificial Intelligence Technology Solutions Inc. filed an 8-K on February 17, 2026, disclosing under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No specific details on the nature of the other events or the content of any exhibits are provided. No quantitative metrics, positive or negative changes, or financial impacts are mentioned.
17-02-2026
17-02-2026
17-02-2026
Science Applications International Corp filed an 8-K on 2026-02-17 disclosing an officer change or related event under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers), along with Regulation FD Disclosure under Item 7.01 and Financial Statements and Exhibits under Item 9.01. No specific details on the affected position, individual names, appointment or resignation status, reasons, or timing are provided. No quantitative financial metrics, performance comparisons, or market impacts are mentioned.
17-02-2026
Disc Medicine, Inc. filed a Form 8-K on February 17, 2026, under Item 7.01 Regulation FD Disclosure, indicating voluntary release of material nonpublic information, and Item 9.01 Financial Statements and Exhibits, likely attaching related materials such as a press release. No specific financial metrics, transactions, events, or quantitative data are disclosed in the provided filing information. Details of the disclosure content remain NOT_DISCLOSED.
17-02-2026
Columbia Financial, Inc. filed an 8-K on February 17, 2026, under Item 5.02 disclosing a departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers. No specific details on affected positions, individuals involved, reasons for the change, timing, or impacts are provided in the available information. This is a required SEC disclosure for material leadership events, but lacks quantitative or qualitative context.
17-02-2026
Tianci International, Inc. filed an 8-K on February 17, 2026, disclosing Item 5.07: Submission of Matters to a Vote of Security Holders. No specific details on the matters submitted, vote outcomes, shareholder turnout, or proposals are provided in the filing summary. This is an informational filing with no financial metrics or quantitative data disclosed.
17-02-2026
Danaher Corp filed a Form 8-K on February 17, 2026, disclosing Other Events under Item 8.01 and Financial Statements and Exhibits under Item 9.01. No specific details regarding the nature of the events, transactions, financial metrics, or exhibits are provided in the filing summary.
17-02-2026
News Corp filed an 8-K on February 17, 2026, reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No specific details regarding the nature of the other events or the contents of the financial statements and exhibits are disclosed. No quantitative metrics, positive or negative changes, or period-over-period comparisons are provided in the filing summary.
17-02-2026
17-02-2026
Cingulate Inc. filed an 8-K on 2026-02-17 disclosing events under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers), alongside Item 3.02 (Unregistered Sales of Equity Securities), Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events), and Item 9.01 (Financial Statements and Exhibits). Specific details including affected positions, names, appointment or resignation status, reasons, and any financial impacts are NOT_DISCLOSED. No quantitative metrics, period-over-period comparisons, or scheduled events were mentioned.
17-02-2026
Cogent Biosciences, Inc. filed a Form 8-K on February 17, 2026 (AccNo: 0001193125-26-053131), disclosing results of operations and financial condition under Item 2.02, with financial statements and exhibits attached under Item 9.01. No specific revenue, earnings, balance sheet details, guidance, or period-over-period comparisons were mentioned. This is a standard financial results announcement without quantified metrics provided.
17-02-2026
Earth Science Tech, Inc. filed an 8-K on 2026-02-17 disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers), along with Regulation FD Disclosure under Item 7.01 and Financial Statements and Exhibits under Item 9.01. No specific details on affected positions, individuals involved, reasons for the change, or any financial metrics are disclosed. No quantitative data, performance comparisons, or scheduled events are mentioned.
17-02-2026
Cineverse Corp. filed an 8-K on February 17, 2026 (AccNo: 0001193125-26-054528), reporting results of operations and financial condition under Item 2.02, accompanied by financial statements and exhibits under Item 9.01. No specific revenue, earnings, balance sheet metrics, period-over-period changes, guidance, or quantitative financial data are disclosed in the provided filing information. The filing size is 527 KB, indicating potential attachments with details not extracted here.
17-02-2026
InPoint Commercial Real Estate Income, Inc. filed a Form 8-K on February 17, 2026, under Item 8.01 (Other Events), which is a voluntary disclosure category for company-determined material information. No specific details regarding the event, financial metrics, transactions, or impacts are disclosed in the provided filing metadata. This informational filing lacks quantitative data or directional indicators.
17-02-2026
CBL & Associates Properties Inc filed an 8-K on 2026-02-17 under Item 5.02 disclosing departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers. Item 9.01 indicates financial statements and exhibits were filed. No specific details on affected positions, individuals, reasons for change, or any quantitative metrics are disclosed.
17-02-2026
Beneficient filed an 8-K on February 17, 2026, reporting under Item 2.02 for Results of Operations and Financial Condition, accompanied by Item 9.01 for Financial Statements and Exhibits. No specific revenue, earnings, balance sheet metrics, period-over-period changes, or quantitative financial data are disclosed in the provided filing details. This represents a standard voluntary earnings disclosure without detailed performance indicators.
17-02-2026
Bayview Acquisition Corp filed an 8-K on 2026-02-17 under Item 3.01, providing notice of delisting or failure to satisfy a continued listing rule or standard, or transfer of listing. No quantitative financial metrics, deal structure details, parties involved, or merger/acquisition specifics are disclosed in the filing summary. Sector is not specified.
17-02-2026
Chemung Financial Corp filed an 8-K on February 17, 2026, reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. This is a multi-item filing with no specific details on the nature of the other events or contents of the exhibits disclosed in the provided information. No financial metrics, transactions, or directional impacts are mentioned.
17-02-2026
CIMG Inc. filed a Form 8-K on February 17, 2026, reporting under Item 1.01 entry into a material definitive agreement, under Item 2.03 creation of a direct financial obligation or an obligation under an off-balance sheet arrangement, and under Item 3.02 unregistered sales of equity securities. Item 9.01 includes financial statements and exhibits. No specific transaction details, dollar values, share counts, or financial impacts are disclosed.
- ·Multi-item 8-K filing (Items 1.01, 2.03, 3.02, 9.01)
17-02-2026
Bally's Corp filed an 8-K on February 17, 2026, disclosing under Item 1.01 entry into a material definitive agreement and under Item 2.03 the creation of a direct financial obligation or an obligation under an off-balance sheet arrangement. Item 9.01 includes financial statements and exhibits. No quantitative details, transaction terms, dollar values, or financial impacts are disclosed.
17-02-2026
Klotho Neurosciences, Inc. filed an 8-K on February 17, 2026, under Item 5.07 reporting the submission of matters to a vote of security holders, typically disclosing results from a shareholder meeting. Item 9.01 discloses financial statements and exhibits. No specific vote results, proposals, financial metrics, or exhibit details are provided in the filing summary.
Get daily alerts with 12 investment signals, 10 risk alerts, 10 opportunities and full AI analysis of all 34 filings
🇺🇸 More from United States
View all →March 25, 2026
US Pre-Market SEC Filings Roundup — March 25, 2026
US Pre-Market SEC Filings Roundup
March 24, 2026
US Merger & Acquisition SEC Filings — March 24, 2026
US Merger & Acquisition SEC Filings
March 24, 2026
US Corporate Board Director Changes SEC Filings — March 24, 2026
US Corporate Board Director Changes SEC Filings
March 24, 2026
US Executive Officer Management Changes SEC — March 24, 2026
US Executive Officer Management Changes SEC